Duloxetine 60 mg/day for the prevention of depressive recurrences:post hoc analyses from a recurrence prevention study
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the efficacy of duloxetine 60 mg/day in the prevention of depressive recurrence in patients with major depressive disorder (MDD). METHODS: Patients having at least three episodes of MDD in the past 5 years received open-label (OL) duloxetine 60-120 mg/day for up to 34 weeks. Patients meeting response criteria were then randomised to either duloxetine or placebo for up to 52 weeks of double-blind maintenance treatment. Only patients taking duloxetine 60 mg/day during the OL phase, and randomised to either duloxetine (remained on 60 mg/day dose) or placebo, were included in this post hoc analysis. The primary outcome measure was time to recurrence of a major depressive episode. The 17-item Hamilton Rating Scale for Depression (HAMD(17)) was used to evaluate depressive symptomatology. Global and physical functioning and pain were also assessed. Safety and tolerability were assessed via analysis of treatment-emergent adverse events (TEAEs), vital signs and weight. RESULTS: A total of 124 patients were randomised to duloxetine 60 mg/day (n = 64) or placebo (n = 60). Time to depressive recurrence was significantly longer in duloxetine-treated patients compared with placebo-treated patients (p = 0.001). During the double-blind maintenance phase, 31.7% of placebo-treated patients experienced a depressive recurrence compared with 12.5% of duloxetine-treated patients (p = 0.004). The HAMD(17) total score and most of its subscales as well as the Clinical Global Impression of Severity (CGI-S), significantly worsened in the placebo group compared with the duloxetine 60 mg/day group. There were no significant differences between treatment groups in TEAEs, discontinuations because of adverse events, vital signs or weight. CONCLUSIONS: Treatment with duloxetine 60 mg/day was associated with a longer time to depressive recurrence and a significantly lower recurrence rate compared with placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Recurrence after recovery from major depressive disorder during 15 years of observational follow-up
Mueller, T. I., Leon, A. C., Keller, M. B., Solomon, D. A., Endicott, J., Coryell, W., Warshaw, M., & Maser, J. D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1000 · Cited by 897
Keller, M. B., Trivedi, M. H., Thase, M. E., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., Friedman, E. S., Gelenberg, A. J., Kocsis, J. H., Dunner, D. L., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0812 · Cited by 116
Perahia, D. G., Gilaberte, I., Wang, F., Wiltse, C. G., Huckins, S. A., Clemens, J. W., Montgomery, S. A., Montejo, A. L., & Detke, M. J. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.4.346 · Cited by 94
Lépine, J.-P., Caillard, V., Bisserbe, J.-C., Troy, S., Hotton, J.-M., Boyer, P., & For the PREVERS Investigators (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.836 · Cited by 83
Kocsis, J. H., Thase, M. E., Trivedi, M. H., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., Friedman, E. S., Gelenberg, A. J., Dunner, D. L., Hirschfeld, R. M. A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0706 · Cited by 67
Long-Term Safety, Tolerability, and Efficacy of Duloxetine in the Treatment of Fibromyalgia
Mease, P. J., Russell, I. J., Kajdasz, D. K., Wiltse, C. G., Detke, M. J., Wohlreich, M. M., Walker, D. J., & Chappell, A. S. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.11.001 · Cited by 54
Self-citationTerra, J. L., & Montgomery, S. A. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199803000-00001 · Cited by 51
Perahia, D. G. S., Maina, G., Thase, M. E., Spann, M. E., Wang, F., Walker, D. J., & Detke, M. J. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04756 · Cited by 47
Self-citation
Research works printed but not linked: 17
- Franchini, 1998, Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study, J Clin Psychiatry, 59, 229, 10.4088/JCP.v59n0504 · DOI · Paper page
- Gilaberte, 2001, Fluoxetine in the prevention of depressive recurrences: a double-blind study, J Clin Psychopharmacol, 21, 417, 10.1097/00004714-200108000-00009 · DOI · Paper page
- Hamilton, 1960, A rating scale for depression, J Neurol Neurosurg Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
- Guy, 1976, ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare Publication (ADM), 76
- Sheehan, 1998, The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10, J Clin Psychiatry, 59, 22
- Faries, 2000, The responsiveness of the Hamilton Depression Rating Scale, J Psychiatr Res, 34, 3, 10.1016/S0022-3956(99)00037-0 · DOI · Paper page
- DeLoach, 1998, The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale, Anesth Analg, 86, 102
- Gahimer, 2007, A retrospective pooled analysis of duloxetine safety in 23,983 subjects, Curr Med Res Opin, 23, 175, 10.1185/030079906X162719 · DOI · Paper page
- Davidson, 2008, Duloxetine treatment for relapse prevention in adults with generalised anxiety disorder: a double-blind placebo-controlled trial, Eur Neuropsychopharmacol, 18, 673, 10.1016/j.euroneuro.2008.05.002 · DOI · Paper page
- Wernicke, 2007, An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies, Drug Saf, 30, 437, 10.2165/00002018-200730050-00007 · DOI
- Wernicke, 2009, Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions, J Diabetes Complications, 23, 349, 10.1016/j.jdiacomp.2008.07.004 · DOI
- Berken, 1984, Weight gain. A side-effect of tricyclic antidepressants, J Affect Disord, 7, 133, 10.1016/0165-0327(84)90031-4 · DOI · Paper page
- Fava, 2000, Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment, J Clin Psychiatry, 61, 863, 10.4088/JCP.v61n1109 · DOI · Paper page
- Wise, 2006, Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical trials, Prim Care Companion J Clin Psychiatry, 8, 269, 10.4088/PCC.v08n0503 · DOI · Paper page
- Bech, 2006, Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder, Psychopharmacology, 188, 273, 10.1007/s00213-006-0505-1 · DOI
- Lobo, 2009, Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation, Clin Pharmacokinet, 48, 189, 10.2165/00003088-200948030-00005 · DOI
- Sharma, 2000, Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor, J Clin Pharmacol, 40, 161, 10.1177/00912700022008810 · DOI · Paper page
Cited by
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
“Several of the studies reviewed found that treatment effects appeared to be superior among patients with multiple (especially ≥3) previous episodes of depression (Montgomery et al., 1993; Teasdale et al., 2000; Lepine et al., 2004; Ma and Teasdale, 2004; Kelin et al., 2010).”
BackgroundBauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199
Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Adverse reactions to duloxetine in depression
Bitter, I., Filipovits, D., & Czobor, P. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.582037 · Cited by 38
Metadata
- Authors
- Kelin, K., Berk, M., Spann, M., Sagman, D., Raskin, J., Walker, D., & Perahia, D.
- Venue
- International Journal of Clinical Practice
- Publisher
- Hindawi Limited
- Published
- 2010-05
- Volume
- 64
- Issue
- 6
- Pages
- 719-726
- ISSN
- 1368-5031 (ISSN-L)
- 1742-1241
- OpenAlex
- W2010267403
- Cited by
- 11
- References
- 9
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1949 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Duloxetine 60 mg/day for the prevention of depressive recurrences:post hoc analyses from a recurrence prevention study. https://app.cochat.ai/papers/10.1111/j.1742-1241.2010.02374.x
- The paper
- Kelin, K., Berk, M., Spann, M., Sagman, D., Raskin, J., Walker, D., & Perahia, D. (2010). Duloxetine 60 mg/day for the prevention of depressive recurrences:post hoc analyses from a recurrence prevention study. International Journal of Clinical Practice. https://doi.org/10.1111/j.1742-1241.2010.02374.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.